Background: There are no established methods for pancreatic cancer (PAC) screening, but the NCI and the Pancreatic Cancer Action Network (PanCAN) are investigating risk-based screening strategies in patients with new-onset diabetes (NOD), a group with elevated PAC risk. Preliminary estimates of the cost-effectiveness of these strategies can provide insights about potential value and inform supplemental data collection. Using data from the Enriching New-Onset Diabetes for Pancreatic Cancer (END-PAC) risk model validation study, we assessed the potential value of CT screening for PAC in those determined to be at elevated risk, as is being done in a planned PanCAN Early Detection Initiative trial. Methods: We created an integrated decision tree and Markov state-transition model to assess the cost-effectiveness of PAC screening in patients aged ≥50 years with NOD using CT imaging versus no screening. PAC prevalence, sensitivity, and specificity were derived from the END-PAC validation study. PAC stage distribution in the no-screening strategy and PAC survival were derived from the SEER program. Background mortality for patients with diabetes, screening and cancer care expenditure, and health state utilities were derived from the literature. Life-years (LYs), quality-adjusted LYs (QALYs), and costs were tracked over a lifetime horizon and discounted at 3% per year. Results are presented in 2020 US dollars, and we took a limited US healthcare perspective. Results: In the base case, screening resulted in 0.0055 more LYs, 0.0045 more QALYs, and $293 in additional expenditures for a cost per QALY gained of $65,076. In probabilistic analyses, screening resulted in a cost per QALY gained of <$50,000 and <$100,000 in 34% and 99% of simulations, respectively. In the threshold analysis, >25% of screen-detected PAC cases needed to be resectable for the cost per QALY gained with screening to be <$100,000. Conclusions: We found that risk-based PAC screening in patients with NOD is likely to be cost-effective in the United States if even a modest fraction (>25%) of screen-detected patients with PAC are resectable. Future studies should reassess the value of this intervention once clinical trial data become available.
Submitted July 10, 2020; final revision received December 14, 2020; accepted for publication December 14, 2020. Published online June 21, 2021.
Contributions:Study concept: All authors. Data curation: Schwartz, Matrisian, Sharder, Chari, Roth. Data analysis: Schwartz, Roth. Manuscript preparation: All authors. Manuscript revision: All authors.
Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Funding: This study was funded by a grant from the Pancreatic Cancer Action Network (J.A. Roth).
Correspondence: Joshua A. Roth, PhD, MHA, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109. Email: firstname.lastname@example.org
SandersGD, NeumannPJ, BasuA, et al.Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA2016;316:1093–1103.
SandersGD, NeumannPJ, BasuA, Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093–1103.2762346310.1001/jama.2016.12195)| false
RoccaWA, YawnBP, St SauverJL, History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc 2012;87:1202–1213.10.1016/j.mayocp.2012.08.012)| false
MaitraA, SharmaA, BrandRE, et al.A prospective study to establish a new-onset diabetes cohort: from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas2018;47:1244–1248.
MaitraA, SharmaA, BrandRE, A prospective study to establish a new-onset diabetes cohort: from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 2018;47:1244–1248.10.1097/MPA.0000000000001169)| false
WrightAK, KontopantelisE, EmsleyR, et al.Life expectancy and cause-specific mortality in type 2 diabetes: a population-based cohort study quantifying relationships in ethnic subgroups. Diabetes Care2017;40:338–345.
WrightAK, KontopantelisE, EmsleyR, Life expectancy and cause-specific mortality in type 2 diabetes: a population-based cohort study quantifying relationships in ethnic subgroups. Diabetes Care 2017;40:338–345.2799891110.2337/dc16-1616)| false
BillingsBJ, ChristeinJD, HarmsenWS, Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg 2005;9:1059–1067.1626937610.1016/j.gassur.2005.05.014)| false
ChoiJG, NippRD, TramontanoA, Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: results of a decision analysis. Oncologist 2019;24: 945–954.10.1634/theoncologist.2018-0114)| false
MengY, McCarthyG, BerthonA, et al.Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours—an analysis based on the CLARINET study. Health Qual Life Outcomes2017;15:131.
MengY, McCarthyG, BerthonA, Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours—an analysis based on the CLARINET study. Health Qual Life Outcomes 2017;15:131.10.1186/s12955-017-0711-z)| false
TramontanoAC, ChenY, WatsonTR, Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Medicine (Baltimore) 2019;98:e18082.10.1097/MD.0000000000018082)| false
ClemensK, GarrisonLPJr, JonesA, Strategic use of pharmacoeconomic research in early drug development and global pricing. Pharmacoeconomics 1993;4:315–322.10.2165/00019053-199304050-0000210146870)| false
ChenW, ButlerRK, LustigovaE, Validation of the enriching new-onset diabetes for pancreatic cancer model in a diverse and integrated healthcare setting. Dig Dis Sci 2021;66:78–87.10.1007/s10620-020-06139-z)| false
GindeAA, FoianiniA, RennerDM, Availability and quality of computed tomography and magnetic resonance imaging equipment in U.S. emergency departments. Acad Emerg Med 2008;15:780–783.1878349110.1111/j.1553-2712.2008.00192.x)| false